Effect of remazolam on plasma NFL concentration and postoperative delirium after non-cardiac major surgery in elderly patients with frailty: a prospective, randomized controlled clinical study

注册号:

Registration number:

ChiCTR2400093862 

最近更新日期:

Date of Last Refreshed on:

2024-12-12 17:42:22 

注册时间:

Date of Registration:

2024-12-12 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

瑞马唑仑对老年衰弱患者非心脏大手术后血浆NFL浓度和术后谵妄的影响:一项前瞻性、随机对照临床研究

Public title:

Effect of remazolam on plasma NFL concentration and postoperative delirium after non-cardiac major surgery in elderly patients with frailty: a prospective, randomized controlled clinical study

注册题目简写:

English Acronym:

Effect of remazolam on plasma NFL concentration and postoperative delirium after non-cardiac major surgery in elderly patients with frailty: a prospective, randomized controlled clinical study

研究课题的正式科学名称:

瑞马唑仑对老年衰弱患者非心脏大手术后血浆NFL浓度和术后谵妄的影响:一项前瞻性、随机对照临床研究

Scientific title:

Effect of remazolam on plasma NFL concentration and postoperative delirium after non-cardiac major surgery in elderly patients with frailty: a prospective, randomized controlled clinical study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

周清河 

研究负责人:

周清河 

Applicant:

Zhou Qinghe 

Study leader:

Zhou Qinghe 

申请注册联系人电话:

Applicant telephone:

+86 137 3257 3379

研究负责人电话:

Study leader's telephone:

+86 13732573379

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

jxxmxy@163.com

研究负责人电子邮件:

Study leader's E-mail:

jxxmxy@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省嘉兴市南湖区中环南路1882号

研究负责人通讯地址:

浙江省嘉兴市南湖区中环南路1882号

Applicant address:

1882 Zhonghuan Road South, Nanhu District, Jiaxing, Zhejiang

Study leader's address:

1882 Zhonghuan Road South, Nanhu District, Jiaxing, Zhejiang

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

嘉兴市第一医院

Applicant's institution:

The First Hospital Of Jiaxing

研究负责人所在单位:

嘉兴市第一医院

Affiliation of the Leader:

The First Hospital Of Jiaxing

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024-LY-755

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

嘉兴市第一医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Jiaxing First Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024-10-22 00:00:00

伦理委员会联系人:

许文

Contact Name of the ethic committee:

Xu Wen

伦理委员会联系地址:

浙江省嘉兴市南湖区中环南路1882号

Contact Address of the ethic committee:

1882 Zhonghuan Road South, Nanhu District, Jiaxing, Zhejiang

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 573 89976378

伦理委员会联系人邮箱:

Contact email of the ethic committee:

xwkikimi@163.com

研究实施负责(组长)单位:

嘉兴市第一医院

Primary sponsor:

The First Hospital Of Jiaxing

研究实施负责(组长)单位地址:

浙江省嘉兴市南湖区中环南路1882号

Primary sponsor's address:

1882 Zhonghuan Road South, Nanhu District, Jiaxing, Zhejiang

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

Country:

China

Province:

Zhejiang

City:

单位(医院):

嘉兴市第一医院

具体地址:

浙江省嘉兴市南湖区中环南路1882号

Institution
hospital:

The First Hospital Of Jiaxing

Address:

1882 Zhonghuan Road South, Nanhu District, Jiaxing, Zhejiang

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Self-raised

Target disease:

Postoperative delirium (POD)

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

通过一项前瞻性、随机双盲临床研究,评估患者的衰弱指数进行危险分层后将患者分为丙泊酚全身麻醉组和瑞马唑仑全身麻醉组,明确瑞马唑仑对老年衰弱患者非心脏大手术后血浆NFL浓度和术后谵妄的影响,为术后谵妄发生的防治提供参考意见和建议。  

Objectives of Study:

Through a prospective, randomized double-blind clinical study, the frailty index of patients was evaluated and risk stratification was performed to divide them into propofol general anesthesia group and remifentanil general anesthesia group. The effect of remifentanil on plasma NFL concentration and postoperative delirium in elderly patients with frailty after non cardiac major surgery was clarified, providing reference opinions and suggestions for the prevention and treatment of postoperative delirium.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.本研究纳入2025年01月至2026年12月的气管插管全身麻醉下行非心脏手术、手术时间>60min的患者,年龄≥60岁,ASA Ⅰ-Ⅲ 级,至少术后在医院时间超过72h。研究已经通过医院伦理委员会审查批准,纳入患者均签署知情同意书。

Inclusion criteria

1.This study included patients who underwent non cardiac surgery under general anesthesia with endotracheal intubation from January 2025 to December 2026, with a surgical duration of>60 minutes, aged >= 60 years, ASA I-III grade, and had stayed in the hospital for at least 72 hours after surgery. The study has been reviewed and approved by the hospital ethics committee, and all included patients have signed informed consent forms.

排除标准:

1.手术仅在局部麻醉、区域麻醉或麻醉监护下进行;2.既往有精神疾病、术前服用抗精神病药物、酒精戒断谵妄的患者;3.二度一型及以上房室传导阻滞、或3个月内急性心肌梗死或中风的患者;4.严重肝肾疾病(肝脏Child-pugh C级,血肌酐>442umol/L)的患者;5.ASA分级达到IV级或更高的患者;6.对任何与试验相关的药物过敏的患者。

Exclusion criteria:

1.The surgery is only performed under local anesthesia, regional anesthesia, or anesthesia monitoring;
2.Patients with previous mental illnesses, preoperative use of antipsychotic drugs, and alcohol withdrawal delirium;
3.Patients with second degree type 1 or above atrioventricular block, or acute myocardial infarction or stroke within 3 months;
4.Patients with severe liver and kidney diseases (Child pugh C grade liver, serum creatinine>442umol/L);
5.Patients with ASA grade IV or higher;
6.Patients who are allergic to any drugs related to the experiment.

研究实施时间:

Study execute time:

From 2025-01-01 00:00:00 To 2026-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-01-01 00:00:00 To 2026-12-31 00:00:00  

干预措施:

Interventions:

组别:

丙泊酚全身麻醉组

样本量:

80

Group:

Propofol general anesthesia group

Sample size:

干预措施:

丙泊酚全身麻醉

干预措施代码:

Intervention:

Propofol general anesthesia

Intervention code:

组别:

瑞马唑仑全身麻醉组

样本量:

80

Group:

Rimazolen general anesthesia group

Sample size:

干预措施:

瑞马唑仑全身麻醉

干预措施代码:

Intervention:

Rimazolen general anesthesia

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China 

Province:

Zhejiang 

City:

 

单位(医院):

嘉兴市第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Hospital Of Jiaxing

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

神经丝轻链NFL

指标类型:

主要指标

Outcome:

Neurofilamentlightchain

Type:

Primary indicator

测量时间点:

麻醉前、手术后即刻、术后1天

测量方法:

血清定量检测

Measure time point of outcome:

Before anesthesia, immediately after surgery, and 1 day after surgery

Measure method:

Serum quantitative detection

指标中文名:

谵妄指标

指标类型:

主要指标

Outcome:

Indicators of delirium

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 60 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

一个独立于本研究的的统计学家为两个中心分别准备了从网络生成的随机数字,随机数字被放置在密封的、按顺序编号的、不透明的信封放置在手术室中

Randomization Procedure (please state who generates the random number sequence and by what method):

A statistician independent of this study prepared random numbers generated from the network for each of the two centers. Random numbers are placed in sealed, sequentially numbered, opaque envelopes in the operating room.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

双盲,对患者和研究者设盲

Blinding:

Double-blind, blinding the patient and the investigator

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

3年后共享原始数据,如有需要邮箱索取。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Share the original data after 3 years, and request it via email if needed.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2024-12-12 17:41:12